Literature DB >> 11746736

Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys.

K M Wilcox1, K P Lindsey, J R Votaw, M M Goodman, L Martarello, F I Carroll, L L Howell.   

Abstract

Dopaminergic mechanisms are thought to play a central role in the reinforcing effects of cocaine. The present study examined the reinforcing effects of 3beta-(4-chlorophenyl)tropane-2beta-carboxylic acid phenyl ester (RTI-113), a long-acting, selective, high-affinity dopamine uptake inhibitor. Additionally, the effects of RTI-113 pretreatment on cocaine self-administration were determined. Monkeys were trained to respond under a second-order schedule for intravenous cocaine administration (0.10 or 0.17 mg/kg/infusion). When responding was stable, cocaine (0.0030-1.0 mg/kg/infusion) and RTI-113 (0.010-0.30 mg/kg/infusion) were substituted for the cocaine training dose. Cocaine and RTI-113 were equipotent for their reinforcing effects. However, cocaine maintained higher response rates in two of the three monkeys tested. When administered as a pretreatment, RTI-113 (0.10-0.30 mg/kg) dose-dependently reduced responding maintained by two doses of cocaine. Drug effects on behavior were related to dopamine transporter (DAT) occupancy in monkey striatum during neuroimaging with positron emission tomography. DAT occupancy was determined by displacement of 8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane (FECNT). DAT occupancy was between 65-76% and 94-99% for doses of cocaine and RTI-113 that maintained maximum response rates, respectively. DAT occupancy did not differ markedly across RTI-113 pretreatment doses and ranged between 72-84%. The results suggest that the pharmacokinetic profile of RTI-113 (i.e., long-acting) may influence its ability to maintain self-administration, and therefore its abuse liability. Additionally, high DAT occupancy is required for RTI-113 to reduce cocaine-maintained responding. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11746736     DOI: 10.1002/syn.10018

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  27 in total

Review 1.  Neuroimaging in drug abuse.

Authors:  Kimberly P Lindsey; S John Gatley; Nora D Volkow
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

2.  The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

Authors:  K S Murnane; H L Kimmel; K C Rice; L L Howell
Journal:  Horm Behav       Date:  2011-12-14       Impact factor: 3.587

3.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

4.  Nonhuman primate positron emission tomography neuroimaging in drug abuse research.

Authors:  Leonard Lee Howell; Kevin Sean Murnane
Journal:  J Pharmacol Exp Ther       Date:  2011-02-11       Impact factor: 4.030

5.  Dopamine transporter-related effects of modafinil in rhesus monkeys.

Authors:  Monica L Andersen; Eileen Kessler; Kevin S Murnane; Jessica C McClung; Sergio Tufik; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

6.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

Review 7.  Nonhuman primate neuroimaging and the neurobiology of psychostimulant addiction.

Authors:  Leonard L Howell; Kevin S Murnane
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

8.  Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters.

Authors:  Prashant S Kharkar; Angela M Batman; Juan Zhen; Patrick M Beardsley; Maarten E A Reith; Aloke K Dutta
Journal:  ChemMedChem       Date:  2009-07       Impact factor: 3.466

Review 9.  Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.

Authors:  Richard B Rothman; Michael H Baumann; Thomas E Prisinzano; Amy Hauck Newman
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

Review 10.  Nonhuman primate neuroimaging and cocaine medication development.

Authors:  Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.